tiprankstipranks
Trending News
More News >
Ardelyx Inc (ARDX)
:ARDX
US Market

Ardelyx (ARDX) Earnings Dates, Call Summary & Reports

Compare
1,664 Followers

Earnings Data

Report Date
Jul 31, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.12
Last Year’s EPS
-0.07
Same Quarter Last Year
Based on 9 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 01, 2025
|
% Change Since: -28.15%
|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights significant revenue growth and strategic progress with IBSRELA and XPHOZAH. However, challenges such as market contractions, Medicare disruptions, and increased expenses were noted. The company's strong cash position and milestone achievement in China provide additional positives.
Company Guidance
During the first quarter of 2025, Ardelyx reported a significant 61% year-over-year revenue growth, reaching $74 million. This growth was driven by robust performances from their commercial products, IBSRELA and XPHOZAH. IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by a strong prescription demand and strategic efforts to enhance prescriber adoption and patient access. The company reaffirmed its 2025 guidance of $240 million to $250 million in net sales and anticipates peak annual net sales revenue exceeding $1 billion for IBSRELA. XPHOZAH, despite market disruptions, grew by 30% from the previous year, excluding adjustments, totaling $23.4 million in net sales revenue. Ardelyx remains confident in achieving a peak sales target of $750 million for XPHOZAH, focusing on non-Medicare segments amid ongoing Medicare Part D changes. The company reported a net loss of $41.1 million and maintained a strong cash position of $214 million as of March 31, 2025.
Significant Revenue Growth
Ardelyx reported a 61% increase in revenue, totaling $74 million compared to the same period last year.
IBSRELA's Strong Performance
IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by strong prescription demand and effective commercial execution.
XPHOZAH's Growth
XPHOZAH revenue grew by 30% compared to last year, with successful patient access across Medicare and non-Medicare segments.
Financial Milestone
Ardelyx earned a $5 million milestone from their partner in China following the approval of Tenapanor for hyperphosphatemia.
Strong Cash Position
As of March 31, 2025, Ardelyx had $214 million in cash, cash equivalents, and short-term investments.

Ardelyx (ARDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ARDX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 31, 2025
2025 (Q2)
-0.12 / -
-0.07
May 01, 2025
2025 (Q1)
-0.11 / -0.17
-0.11-54.55% (-0.06)
Feb 20, 2025
2024 (Q4)
<0.01 / 0.02
-0.12116.67% (+0.14)
Oct 31, 2024
2024 (Q3)
-0.05 / 0.00
0.03
Aug 01, 2024
2024 (Q2)
-0.11 / -0.07
-0.0812.50% (<+0.01)
May 02, 2024
2024 (Q1)
-0.15 / -0.11
-0.1315.38% (+0.02)
Feb 22, 2024
2023 (Q4)
-0.10 / -0.12
0.06-300.00% (-0.18)
Oct 31, 2023
2023 (Q3)
-0.11 / 0.03
-0.14121.43% (+0.17)
Aug 02, 2023
2023 (Q2)
-0.12 / -0.08
-0.1957.89% (+0.11)
May 03, 2023
2023 (Q1)
-0.10 / -0.13
-0.2138.10% (+0.08)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ARDX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 01, 2025
$5.47$4.13-24.50%
Feb 20, 2025
$6.36$5.72-10.06%
Oct 31, 2024
$5.87$6.09+3.75%
Aug 01, 2024
$5.50$6.05+10.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ardelyx Inc (ARDX) report earnings?
Ardelyx Inc (ARDX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
    What is Ardelyx Inc (ARDX) earnings time?
    Ardelyx Inc (ARDX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ARDX EPS forecast?
          ARDX EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.

            Ardelyx (ARDX) Earnings News

            Ardelyx Soars on Q4 Beat; Ibsrela Impresses
            Premium
            Market News
            Ardelyx Soars on Q4 Beat; Ibsrela Impresses
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis